An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

The U.S. Food and Drug Administration has approved Amneal Pharmaceuticals' self-administered migraine drug, giving way to a ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for earnings, it missed the same for sales. Earnings of 92 cents per share ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Global pharmaceutical company Pfizer Inc. is donating $750,000 to bolster tribal health care services in Oklahoma, with three Indigenous-operated clinics set to receive funding. The one-time ...

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker.